SPOTLIGHT -
London-The European Commission (EC) has approved Allergan Inc.'s bimatoprost ophthalmic solution 0.03% (Lumigan) as a first-line therapy to reduce IOP in chronic open-angle glaucoma and ocular hypertension.
Phoenix-Micron Inc and ArtiKode Intelligence team up to enhance OCT imaging with AI
(EyePod) From idea to impact: Navigating ophthalmic innovation
Orbis, FundamentalVR team up to target training
EyePod: Modifier Gene Therapy: What is it?
ARVO flying high in Seattle
Intracortical Visual Prosthesis achieves 2 years of successful testing